Therapy combining dinutuximab with granulocyte macrophage colony stimulating factor, interleukin 2, and isotretinoin has significant side effects; however, these complications are generally predictable and can be managed proactively.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1043454216659448 | DOI Listing |
Publication Analysis
Top Keywords
dinutuximab novel
4
novel immunotherapy
4
immunotherapy treatment
4
treatment pediatric
4
pediatric patients
4
patients high-risk
4
high-risk neuroblastoma
4
neuroblastoma [formula
4
[formula text]
4
text] therapy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!